Active, not recruitingPhase 3NCT04974398

A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Studying Nasopharyngeal carcinoma

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Akeso
Principal Investigator: Chaosu Hu, MD
Fudan University
Intervention: Penpulimab(drug)
Enrollment: 296 target
Eligibility: 12-75 years · All sexes
Timeline: 2021 – 2026

Study locations (30)

City of Hope, Duarte, California, United States
Winship Cancer Institute/Emory University, Atlanta, Georgia, United States
University of Michigan, Ann Arbor, Michigan, United States
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
St Vincent's Public Hospital Sydney, Darlinghurst, New South Wales, Australia
Genesis Care North Shore, St Leonards, New South Wales, Australia
Sir Charles Gardner, Heidelberg, Victoria, Australia
Austin Health, Nedlands, Western Australia, Australia
Hospital de Câncer de Barretos - Fundação Pio XII, Barretos, REG1, Brazil
Grupo Oncoclínicas, Botafogo, REG1, Brazil
Hospital Bruno Born, Lajeado, REG1, Brazil
Hospital Nossa Senhora da Conceicao, Porto Alegre, REG1, Brazil
Centro de Estudos e Pesquisa de Hematologia, Santo André, REG1, Brazil
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04974398 on ClinicalTrials.gov

Other trials for Nasopharyngeal carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Nasopharyngeal carcinoma →

← Back to all trials